GPT and pancreatitis: Serious adverse events (SAEs) were reported for 3 subjects (8%)– 2 subjects (22%) in 250 mg group (Pneumonitis, Pancreatitis) and 1 subject (9%) in 1000 mg group (ALT and Bilirubin increased).